Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 6/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | RCE1 | Q9Y256 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.31 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4698850 | 0.90 | BDKRB2 (0.35) | GAAMAPTTDP1LMNASMN1; SMN2 | |
| SCHEMBL6385280 | 0.87 | GAA (0.38) | GAAMAPTKMT2AKDM4ECYP2C19 | |
| SCHEMBL4698835 | 0.85 | ROCK2 (0.36) | GAAMAPTLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL4700441 | 0.81 | BDKRB2 (0.38) | MAPTKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL6385415 | 0.81 | KMT2A (0.37) | GAAMAPTKMT2AKDM4ECYP2C19 | |
| SCHEMBL6391408 | 0.81 | ALDH1A1 (0.39) | GAAMAPTTDP1LMNASMN1; SMN2 | |
| SCHEMBL4702236 | 0.80 | P2RY12 (0.34) | GAAMAPTKMT2AMEN1L3MBTL1 | |
| SCHEMBL6387777 | 0.79 | KDM4E (0.42) | GAAMAPTKMT2AKDM4EMEN1 | |
| SCHEMBL6385743 | 0.79 | ALDH1A1 (0.41) | KMT2ACYP2C19MEN1TDP1SMN1; SMN2 | |
| SCHEMBL6389727 | 0.79 | ALDH1A1 (0.41) | KMT2ACYP2C19MEN1TDP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1458684-B1 | THERAPEUTIC HETEROCYCLES AS BRADYKININ B2 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-01-16 | — | — | EP | claimed |
| EP-1458684-B1 | THERAPEUTIC HETEROCYCLES AS BRADYKININ B2 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-01-16 | — | — | EP | disclosed |
| US-20050245503-A1 | Therapeutic heterocycles | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245503-A1 | Therapeutic heterocycles | OPRK1, RECQL, OPRM1 | GAA 1270/4885MAPT 4133/4885KMT2A 1888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.